Publisher Correction: Current knowledge and challenges of sepsis-associated encephalopathy - Scorecard - MDSpire

Publisher Correction: Current knowledge and challenges of sepsis-associated encephalopathy

  • By

  • Manu Shankar-Hari

  • Sarah Benghanem

  • Lena Bourhy

  • Colm Cunningham

  • Johannes Ehler

  • Timothy D. Girard

  • Teneille E. Gofton

  • Bertrand Hermann

  • Zoeb Jiwaji

  • Aurelien Mazeraud

  • Ed Needham

  • Regis G. Rosa

  • Mervyn Singer

  • Arjen J. C. Slooter

  • Romain Sonneville

  • Robert D. Stevens

  • Fabio Silvio Taccone

  • Tarek Sharshar

  • July 2, 2026

  • 0 min

Share

Clinical Scorecard: Correction Notice: Understanding Sepsis-Related Encephalopathy: Insights and Ongoing Challenges

At a Glance

CategoryDetail
ConditionSepsis-Related Encephalopathy
Key MechanismsNot specified
Target PopulationNot specified
Care SettingIntensive Care

Key Highlights

  • Correction of author's name from 'Ed Neeham' to 'Needham'
  • Publisher issued an apology for the mistake
  • The original article has been updated

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified

          Not specified

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Publisher Correction: Current knowledge and challenges of sepsis-associated encephalopathy

            • by Manu Shankar-Hari, Sarah Benghanem, Lena Bourhy, Colm Cunningham, Johannes Ehler, Timothy D. Girard, Teneille E. Gofton, Bertrand Hermann, Zoeb Jiwaji, Aurelien Mazeraud, Ed Needham, Regis G. Rosa, Mervyn Singer, Arjen J. C. Slooter, Romain Sonneville, Robert D. Stevens, Fabio Silvio Taccone, Tarek Sharshar

            • July 2, 2026

            Related Content

            Adverse effects of systemic therapy in a patient with urothelial bladder cancer and chronic kidney disease – a case report

            Retinal connections to migraine

            Comparing the real-world effectiveness of botulinum toxin type A injections across distinct poststroke muscle hyper-resistance patterns